Roger Susi Sells 2,500 Shares of iRadimed (NASDAQ:IRMD) Stock

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 2,500 shares of iRadimed stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $87.88, for a total transaction of $219,700.00. Following the completion of the transaction, the chief executive officer directly owned 2,172,500 shares in the company, valued at approximately $190,919,300. This trade represents a 0.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

iRadimed Price Performance

IRMD stock opened at $93.17 on Friday. The firm has a market capitalization of $1.19 billion, a P/E ratio of 50.91 and a beta of 0.90. iRadimed Corporation has a 52-week low of $50.88 and a 52-week high of $107.90. The company’s 50 day simple moving average is $92.91 and its 200-day simple moving average is $95.13.

iRadimed (NASDAQ:IRMD) last posted its quarterly earnings data on Friday, May 1st. The medical equipment provider reported $0.49 EPS for the quarter, topping analysts’ consensus estimates of $0.46 by $0.03. The firm had revenue of $21.98 million during the quarter, compared to analyst estimates of $21.32 million. iRadimed had a net margin of 27.36% and a return on equity of 24.48%. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. Sell-side analysts predict that iRadimed Corporation will post 1.52 EPS for the current fiscal year.

iRadimed Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 29th. Investors of record on Friday, May 15th will be paid a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Friday, May 15th. iRadimed’s dividend payout ratio is currently 43.72%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on IRMD. Weiss Ratings upgraded iRadimed from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, May 6th. Roth Mkm reaffirmed a “buy” rating and set a $120.00 price objective on shares of iRadimed in a research report on Tuesday, February 10th. Freedom Capital upgraded shares of iRadimed to a “strong-buy” rating in a research note on Thursday, April 2nd. Finally, Lake Street Capital reiterated a “buy” rating and issued a $120.00 target price on shares of iRadimed in a research report on Wednesday, February 11th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $120.00.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of IRMD. Vanguard Group Inc. raised its stake in shares of iRadimed by 1.0% during the 3rd quarter. Vanguard Group Inc. now owns 566,507 shares of the medical equipment provider’s stock worth $40,313,000 after purchasing an additional 5,475 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its stake in shares of iRadimed by 410.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 255,887 shares of the medical equipment provider’s stock valued at $24,893,000 after buying an additional 205,783 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in iRadimed by 4.2% in the first quarter. Dimensional Fund Advisors LP now owns 226,146 shares of the medical equipment provider’s stock worth $21,768,000 after buying an additional 9,017 shares during the last quarter. Goldman Sachs Group Inc. raised its position in iRadimed by 37.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 205,227 shares of the medical equipment provider’s stock valued at $19,964,000 after acquiring an additional 55,426 shares in the last quarter. Finally, State Street Corp raised its position in iRadimed by 3.1% during the fourth quarter. State Street Corp now owns 192,952 shares of the medical equipment provider’s stock valued at $18,770,000 after acquiring an additional 5,713 shares in the last quarter. 92.34% of the stock is owned by institutional investors and hedge funds.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.